Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. It blocks viral entry into host cells while preserving normal immunologic function. The Company is also investigating an intramuscular method of administration of Trogarzo. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy.


TSX:TH - Post by User

Comment by scarlet1967on Jun 26, 2022 9:16pm
162 Views
Post# 34783585

RE:RE:RE:RE:RE:RE:RE:RE:RE:Excess of adipose visceral fat causing NAFLD regardless of..

RE:RE:RE:RE:RE:RE:RE:RE:RE:Excess of adipose visceral fat causing NAFLD regardless of..

Questions you may want to consider

If your healthcare provider is thinking about using an approved drug for an unapproved use, you may want to ask your healthcare provider questions like these:

  • What is the drug approved for?
  • Are there other drugs or therapies that are approved to treat my disease or medical condition?
  • What scientific studies are available to support the use of this drug to treat my disease or medical condition?
  • Is it likely that this drug will work better to treat my disease or medical condition than using an approved treatment?
  • What are the potential benefits and risks of treating my disease or medical condition with this drug?
  • Will my health insurance cover treatment of my disease or medical condition with this drug? 
  • Are there any clinical trials studying the use of this drug for my disease or medical condition that I could enroll in?

 

https://www.fda.gov/patients/learn-about-expanded-access-and-other-treatment-options/understanding-unapproved-use-approved-drugs-label

 

 

Off label prescriptions the way I see it are not financially scalable for various reasons, the drug’s label set by authorities is limited to the condition it was approved for so in case of adverse side effects the prescribing physician can get in trouble not sure many legit physicians are happy to take that risk also the insurance issue.

Point is the whole idea of clinical trials are to get that label. Now PLWH suffering from lipodystrophy and NAFLD/NASH could be legitimately prescribed Tesamorelin but as for general NASH we need that label.

 

<< Previous
Bullboard Posts
Next >>

USER FEEDBACK SURVEY ×

Be the voice that helps shape the content on site!

At Stockhouse, we’re committed to delivering content that matters to you. Your insights are key in shaping our strategy. Take a few minutes to share your feedback and help influence what you see on our site!

The Market Online in partnership with Stockhouse